ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Use, understanding, and perceptions of gut microbiome research and practices in oncology.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe gut microbiome has gained increasing recognition as an important factor influencing cancer treatment efficacy and toxicity. However, translation of this knowledge to deliver clinical benefit has been hampered by inconsistent approaches to both biospecimen sampling and investigation of microbial-based interventions, potentially reflecting inherent biases and/or barriers across research environments. Accordingly, we aimed to characterize the current practices and perceptions surrounding the gut microbiome among members of the Multinational Association of Supportive Care in Cancer (MASCC).
methodsA mixed-methods survey, probing current research and/or clinical use, plans, and perceptions of the gut microbiome in oncology, was developed in 2022 and distributed MASCC-wide via REDCap. Quantitative data were summarized using descriptive analyses, and qualitative responses were independently dual-coded using inductive thematic analysis.
resultsOut of 117 respondents, the majority (83%) held the belief that the gut microbiome plays an important role in disease states such as cancer. 44.4% of survey respondents reported ongoing research or clinical practice regarding the gut microbiome at their center, with 70.5% also expressing an interest in developing such a program. Qualitative analysis revealed 6 main themes: (1) state of the evidence, (2) significance of the microbiome, (3) uncertainty, (4) aspirations, (5) preferences, and (6) critique.
conclusionsThis survey identifies general concordance on the importance of the gut microbiome in cancer. Despite interest in this field, there is a clear need for resource support (i.e., funding and infrastructure) and increased expertise to support high-quality trials generating the evidence required for implementation of microbial-based sampling or therapeutics in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.